The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Novel HER2 therapies show strong intracranial efficacy, enabling systemic treatment over local therapy for small, ...

BC, OCN, explained that comprehensive disease and treatment education are essential to adherence for patients with breast ...

Repeat biopsies in patients with TNBC may detect changes in HER2 status and allow more patients to gain access to T-DXd, data suggest.

Dr. Kevin Kalinsky covers the gamut of the current treatment landscape for patients with HER2-negative breast cancer, ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer. The innovative approach targets human epidermal growth factor receptor 2-positive, estrogen ...

Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant ...

Immunotherapy, or antibody treatment that activates the patient's own immune system against cancer, is increasingly being studied as an alternative to chemotherapy and radiotherapy. This is because it ...

Sermonix Pharmaceuticals and Regor have announced a strategic partnership aimed at developing therapeutics in the breast ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from ...